heteroarylpiperidine - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	heteroarylpiperidine	go back to main search page
Accession:	CHEBI:48585	browse the term
Synonyms:	related_synonym:	heteroarylpiperidines

show annotations for term's descendants Sort by:
Rat (149) Mouse (149) Human (149) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (149)

crizotinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases activity

crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
crizotinib results in decreased activity of ABCB1 protein

PMID:22233293 PMID:28369651

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily G member 2

decreases activity

crizotinib results in decreased activity of ABCG2 protein

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

decreases activity

crizotinib results in decreased activity of ABL1 protein

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

acetyl-CoA carboxylase alpha

increases phosphorylation

crizotinib results in increased phosphorylation of ACACA protein

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

crizotinib results in decreased phosphorylation of AKT1 protein
EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]

PMID:22553343 PMID:22729845

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

ALK receptor tyrosine kinase

decreases response to substance
affects response to substance
decreases activity
increases mutagenesis
decreases stability
decreases phosphorylation
multiple interactions

ALK gene mutant form results in decreased susceptibility to crizotinib; ALK gene SNP results in decreased susceptibility to crizotinib; ALK protein mutant form results in decreased susceptibility to crizotinib
ALK protein affects the susceptibility to crizotinib
crizotinib results in decreased activity of ALK protein mutant form
crizotinib results in increased mutagenesis of ALK gene mutant form; crizotinib results in increased mutagenesis of ALK protein mutant form
crizotinib results in decreased stability of ALK protein mutant form
crizotinib results in decreased phosphorylation of ALK protein; crizotinib results in decreased phosphorylation of ALK protein mutant form
Crizotinib results in decreased activity of ALK protein; Crizotinib results in decreased activity of ALK protein mutant form
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein; [Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; [Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib; ALK gene SNP inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein mutant form]; ALK protein mutant form inhibits the reaction [crizotinib binds to and results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]; crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form

PMID:20979473 PMID:21030459 PMID:21502504 PMID:21767331 PMID:21791641 More...

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

Bcl2-like 11

increases expression
multiple interactions
affects response to substance

crizotinib results in increased expression of BCL2L11 protein
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein]
BCL2L11 protein affects the susceptibility to crizotinib

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

baculoviral IAP repeat-containing 2

decreases expression
multiple interactions

crizotinib results in decreased expression of BIRC2 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 5

decreases expression
multiple interactions

crizotinib results in decreased expression of BIRC5 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

calcium voltage-gated channel subunit alpha1 C

decreases activity

crizotinib results in decreased activity of CACNA1C protein

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

caspase 3

multiple interactions
increases cleavage
increases activity

BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein]
[crizotinib co-treated with 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] results in increased cleavage of CASP3 protein
crizotinib results in increased activity of CASP3 protein

PMID:22729845 PMID:22789543 PMID:23707608

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity

crizotinib results in increased activity of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases cleavage

Crizotinib results in increased cleavage of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

CD44 molecule

decreases expression

crizotinib results in decreased expression of CD44 mRNA; crizotinib results in decreased expression of CD44 protein

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cytidine deaminase

decreases expression
multiple interactions

crizotinib results in decreased expression of CDA protein
[Crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to Gemcitabine

NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231

G

CRK like proto-oncogene, adaptor protein

multiple interactions

[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein

NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

Crizotinib results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

epidermal growth factor

multiple interactions
decreases response to substance

EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to crizotinib]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

decreases response to substance
multiple interactions

EGFR protein mutant form results in decreased susceptibility to crizotinib; EGFR protein results in decreased susceptibility to crizotinib
[EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]

PMID:21791641 PMID:22235099 PMID:22277784 PMID:22553343

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

EMAP like 4

decreases stability
multiple interactions
increases mutagenesis

crizotinib results in decreased stability of EML4 protein mutant form
[crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib

PMID:21502504 PMID:22912387

NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879

G

epithelial cell adhesion molecule

decreases expression

crizotinib results in decreased expression of EPCAM mRNA; crizotinib results in decreased expression of EPCAM protein

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

coagulation factor III, tissue factor

increases expression

crizotinib results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid desaturase 2

increases expression

crizotinib results in increased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

fatty acid synthase

increases expression

crizotinib results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

Fibroblast growth factor receptor 1

multiple interactions

[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

follicle stimulating hormone subunit beta

decreases secretion

crizotinib results in decreased secretion of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glutamic--pyruvic transaminase

increases secretion

Crizotinib results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

H2A.X variant histone

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Crizotinib results in increased phosphorylation of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

heparin-binding EGF-like growth factor

multiple interactions
decreases response to substance

EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

hepatocyte growth factor

multiple interactions

[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

crizotinib results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

crizotinib results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

insulin induced gene 1

increases expression

crizotinib results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

IQ motif containing GTPase activating protein 1

decreases phosphorylation

Crizotinib results in decreased phosphorylation of IQGAP1 protein

NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755

G

potassium voltage-gated channel subfamily H member 2

decreases activity

crizotinib results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

KIT proto-oncogene receptor tyrosine kinase

decreases response to substance

KIT gene mutant form results in decreased susceptibility to crizotinib

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KRAS proto-oncogene, GTPase

decreases response to substance

KRAS protein mutant form results in decreased susceptibility to crizotinib

NCBI chr 4:178,185,418...178,218,484

G

LCK proto-oncogene, Src family tyrosine kinase

decreases activity

crizotinib results in decreased activity of LCK protein

NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794

G

luteinizing hormone subunit beta

decreases secretion

crizotinib results in decreased secretion of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]

PMID:21266357 PMID:21502504 PMID:22034911 PMID:22553343 PMID:22683780 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

[[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]
crizotinib results in decreased phosphorylation of MAPK3 protein

PMID:21266357 PMID:21502504 PMID:22034911 PMID:22553343 PMID:22683780 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MET proto-oncogene, receptor tyrosine kinase

decreases activity
affects response to substance
increases response to substance
increases mutagenesis
multiple interactions
decreases phosphorylation

crizotinib results in decreased activity of MET protein
MET protein affects the susceptibility to Crizotinib
MET gene mutant form results in increased susceptibility to crizotinib
crizotinib results in increased mutagenesis of MET protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [Crizotinib results in increased mutagenesis of MET protein] inhibits the reaction [Crizotinib binds to and results in decreased activity of MET protein]; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Crizotinib binds to and results in decreased activity of MET protein; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of STAT3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BCL2L11 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC2 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC5 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of XIAP protein]

PMID:21266357 PMID:21405128 PMID:21812414 PMID:22233293 PMID:22683780 More...

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

macrophage stimulating 1 receptor

decreases activity

crizotinib results in decreased activity of MST1R protein

NCBI chr 8:108,596,100...108,611,441
Ensembl chr 8:108,597,299...108,612,455

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions

Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Crizotinib results in increased cleavage of PARP1 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Crizotinib results in increased cleavage of PARP1 protein]

PMID:31639374 PMID:31706006

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

prominin 1

decreases expression

crizotinib results in decreased expression of PROM1 mRNA; crizotinib results in decreased expression of PROM1 protein

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

ribosomal protein S6

decreases phosphorylation

crizotinib results in decreased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

sodium voltage-gated channel alpha subunit 5

decreases activity

crizotinib results in decreased activity of SCN5A protein

NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769

G

sterol regulatory element binding transcription factor 2

increases expression

crizotinib results in increased expression of SREBF2 mRNA

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

signal transducer and activator of transcription 3

decreases phosphorylation
multiple interactions

crizotinib results in decreased phosphorylation of STAT3 protein
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]

PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

TEK receptor tyrosine kinase

decreases activity

crizotinib results in decreased activity of TEK protein

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804

G

transforming growth factor alpha

multiple interactions
decreases response to substance

EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

twist family bHLH transcription factor 1

decreases response to substance

TWIST1 protein results in decreased susceptibility to crizotinib

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

vimentin

decreases expression

crizotinib results in decreased expression of VIM protein

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

X-linked inhibitor of apoptosis

decreases expression
multiple interactions

crizotinib results in decreased expression of XIAP protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

domperidone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects response to substance

ABCB1 gene SNP affects the susceptibility to Domperidone

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

adrenoceptor alpha 1D

affects response to substance

ADRA1D gene SNP affects the susceptibility to Domperidone

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

C-X-C motif chemokine ligand 2

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Domperidone results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases hydroxylation

CYP1A2 protein results in increased hydroxylation of Domperidone

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases hydroxylation

CYP2B6 protein results in increased hydroxylation of Domperidone

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases hydroxylation

CYP2C8 protein results in increased hydroxylation of Domperidone

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases hydroxylation

CYP2D6 protein results in increased hydroxylation of Domperidone

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

CYP3A4 protein results in increased hydroxylation of and results in decreased alkylation of Domperidone

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

dopamine receptor D1

multiple interactions
affects binding

Cyclosporine promotes the reaction [Domperidone binds to DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions
affects binding

Cyclosporine promotes the reaction [Domperidone binds to DRD2 protein]
Domperidone binds to and results in decreased activity of DRD2 protein

PMID:2571179 PMID:8103596 PMID:10626749 PMID:12071432 PMID:12130853 More...

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

interleukin 6

decreases expression

Domperidone results in decreased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions
affects response to substance

Domperidone results in decreased activity of KCNH2 protein
Domperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
KCNH2 gene SNP affects the susceptibility to Domperidone

PMID:15640612 PMID:19583963 PMID:21063774 PMID:28551711

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

myeloperoxidase

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prolactin

multiple interactions
increases expression

Domperidone inhibits the reaction [Deoxyepinephrine results in decreased expression of PRL protein]; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein]
Domperidone results in increased expression of PRL protein

PMID:1304515 PMID:1874184 PMID:6736848 PMID:8532072

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

solute carrier family 22 member 2

multiple interactions

Domperidone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

transforming growth factor, beta 1

decreases expression

Domperidone results in decreased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

thyroid hormone receptor alpha

multiple interactions

Domperidone binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

lonafarnib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

[Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2, apoptosis regulator

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]

PMID:15090542 PMID:16118318

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

multiple interactions

lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

baculoviral IAP repeat-containing 2

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

multiple interactions

[lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

[lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage

[lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein
lonafarnib results in increased cleavage of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of CFLAR protein]

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

glycogen synthase kinase 3 alpha

multiple interactions

[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form

NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802

G

glycogen synthase kinase 3 beta

multiple interactions

[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

HRas proto-oncogene, GTPase

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased activity of HRAS protein]

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

interleukin 18

multiple interactions

geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

lamin A/C

decreases farnesylation

lonafarnib results in decreased farnesylation of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

matrix metallopeptidase 9

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear factor kappa B subunit 1

multiple interactions

lonafarnib inhibits the reaction [Hydrogen Peroxide results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

prostaglandin-endoperoxide synthase 2

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RB transcriptional corepressor 1

multiple interactions

lonafarnib results in decreased phosphorylation of and results in decreased activity of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

lonafarnib inhibits the reaction [Hydrogen Peroxide results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein]; lonafarnib inhibits the reaction [TNF protein affects the localization of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

Ras homolog, mTORC1 binding

decreases activity
multiple interactions

lonafarnib results in decreased activity of RHEB protein
[lonafarnib results in decreased activity of RHEB protein] which results in increased susceptibility to Cisplatin

NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160

G

tumor necrosis factor

multiple interactions

lonafarnib inhibits the reaction [TNF protein affects the localization of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of HRAS protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of TRAF1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of XIAP protein]; lonafarnib inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]

PMID:15090542 PMID:21430599

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor-associated factor 1

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of TRAF1 protein]

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

X-linked inhibitor of apoptosis

multiple interactions

lonafarnib inhibits the reaction [TNF protein results in increased expression of XIAP protein]

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

nadifloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

nadifloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

naratriptan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 1B

affects binding

naratriptan binds to HTR1B protein

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 1D

affects binding

naratriptan binds to HTR1D protein

NCBI chr 5:148,656,252...148,676,532
Ensembl chr 5:148,674,495...148,675,619

paliperidone palmitate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects abundance
multiple interactions
increases export
increases transport
affects response to substance
decreases activity

ABCB1 gene polymorphism affects the abundance of Paliperidone Palmitate; ABCB1 protein affects the abundance of Paliperidone Palmitate
Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Paliperidone Palmitate]
ABCB1A protein results in increased transport of Paliperidone Palmitate
ABCB1A protein affects the susceptibility to Paliperidone Palmitate
Paliperidone Palmitate results in decreased activity of ABCB1 protein
Paliperidone Palmitate inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin]
ABCB1 protein results in increased transport of Paliperidone Palmitate

PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17541883 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects response to substance

ABCB1B protein affects the susceptibility to Paliperidone Palmitate

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

decreases activity

Paliperidone Palmitate results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily G member 2

multiple interactions

Paliperidone Palmitate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

brain-derived neurotrophic factor

increases expression

Paliperidone Palmitate results in increased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects abundance

CYP2D6 gene polymorphism affects the abundance of Paliperidone Palmitate; CYP2D6 protein affects the abundance of Paliperidone Palmitate

PMID:10639689 PMID:15089809 PMID:17541883

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

dopamine receptor D2

multiple interactions
affects binding

Paliperidone Palmitate binds to and results in decreased activity of DRD2 protein
Paliperidone Palmitate binds to DRD2 protein

PMID:19713555 PMID:22437487

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

fatty acid desaturase 2

increases expression
multiple interactions

Paliperidone Palmitate results in increased expression of FADS2 mRNA
[Paliperidone Palmitate results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

5-hydroxytryptamine receptor 2A

affects binding
multiple interactions

Paliperidone Palmitate binds to HTR2A protein
Paliperidone Palmitate binds to and results in decreased activity of HTR2A protein

PMID:7520908 PMID:19713555 PMID:22437487

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 7

multiple interactions

[Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein

PMID:18996971 PMID:19509219 PMID:20827463

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

interleukin 1 alpha

increases expression

Paliperidone Palmitate results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

Paliperidone Palmitate results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

Paliperidone Palmitate results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Paliperidone Palmitate results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

prolactin

increases expression

Paliperidone Palmitate results in increased expression of PRL protein

PMID:17460786 PMID:19825908

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

pimozide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

decreases expression

Pimozide results in decreased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

istradefylline inhibits the reaction [Pimozide results in increased expression of FOS protein]; Tropicamide promotes the reaction [Pimozide results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

potassium voltage-gated channel subfamily A member 10

multiple interactions

Pimozide inhibits the reaction [KCNA10 protein results in increased transport of Potassium]

NCBI chr 2:194,786,500...194,798,575
Ensembl chr 2:194,786,500...194,798,575

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases activity

Pimozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Pimozide results in decreased activity of KCNH2 protein

PMID:15671647 PMID:19583963 PMID:21158687 PMID:24052561

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

luteinizing hormone subunit beta

multiple interactions

Pimozide results in decreased secretion of and results in decreased glycosylation of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

prolactin

increases expression

Pimozide results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

risperidone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects abundance
affects response to substance
increases response to substance
multiple interactions
increases transport
increases export
decreases activity

ABCB1 gene polymorphism affects the abundance of Risperidone; ABCB1 protein affects the abundance of Risperidone
ABCB1 gene polymorphism affects the susceptibility to Risperidone; ABCB1 protein affects the susceptibility to Risperidone
ABCB1 protein results in increased susceptibility to Risperidone
Risperidone inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin]
ABCB1 protein results in increased transport of Risperidone
ABCB1A protein affects the susceptibility to Risperidone
ABCB1A protein results in increased export of Risperidone
Risperidone results in decreased activity of ABCB1 protein
ABCB1A protein results in increased transport of Risperidone
Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Risperidone]

PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17054409 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects response to substance

ABCB1B protein affects the susceptibility to Risperidone

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily G member 2

multiple interactions

Risperidone inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

adiponectin, C1Q and collagen domain containing

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

brain-derived neurotrophic factor

decreases expression
multiple interactions

Risperidone results in decreased expression of BDNF mRNA
Risperidone inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA]
BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]

PMID:12393228 PMID:17442543 PMID:19997080

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

calmodulin 2

increases expression

Risperidone results in increased expression of CALM2 mRNA

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calcium/calmodulin-dependent protein kinase II alpha

decreases expression

Risperidone results in decreased expression of CAMK2A protein

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

calcium/calmodulin-dependent protein kinase IV

decreases expression

Risperidone results in decreased expression of CAMK4 protein

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calcium/calmodulin-dependent protein kinase kinase 1

decreases expression

Risperidone results in decreased expression of CAMKK1 protein

NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498

G

calcium/calmodulin-dependent protein kinase kinase 2

decreases expression

Risperidone results in decreased expression of CAMKK2 protein

NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279

G

caspase 3

multiple interactions
increases activity

Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions
increases activity

Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

CCAAT/enhancer binding protein alpha

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein]
Risperidone results in increased expression of CEBPA mRNA; Risperidone results in increased expression of CEBPA protein

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

cholinergic receptor, muscarinic 4

affects response to substance

CHRM4 affects the susceptibility to Risperidone

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

catechol-O-methyltransferase

increases expression

Risperidone results in increased expression of COMT mRNA

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

corticotropin releasing hormone

decreases expression

Risperidone results in decreased expression of CRH mRNA

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

catenin beta 1

multiple interactions
increases expression

DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing
multiple interactions
affects abundance
decreases metabolic processing
decreases hydroxylation
affects response to substance
increases response to substance
increases metabolic processing

CYP2D6 gene polymorphism affects the metabolism of Risperidone; CYP2D6 protein affects the metabolism of Risperidone
CYP2D6 gene polymorphism affects the metabolism of and affects the abundance of Risperidone; CYP2D6 protein affects the metabolism of and affects the abundance of Risperidone
CYP2D6 gene polymorphism affects the abundance of Risperidone; CYP2D6 protein affects the abundance of Risperidone
CYP2D6 gene polymorphism results in decreased metabolism of Risperidone
CYP2D6 gene polymorphism results in decreased hydroxylation of Risperidone
CYP2D6 gene polymorphism affects the susceptibility to Risperidone; CYP2D6 protein polymorphism affects the susceptibility to Risperidone
CYP2D6 protein results in increased susceptibility to Risperidone
CYP2D6 protein results in increased metabolism of Risperidone

PMID:10639689 PMID:15089809 PMID:15260906 PMID:15565299 PMID:15669884 More...

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects response to substance

N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]
CYP3A4 gene polymorphism affects the susceptibility to Risperidone; CYP3A4 protein affects the susceptibility to Risperidone

PMID:19395426 PMID:21402137

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects abundance
increases metabolic processing

CYP3A5 gene polymorphism affects the abundance of Risperidone; CYP3A5 protein affects the abundance of Risperidone
CYP3A5 protein results in increased metabolism of Risperidone

PMID:18708991 PMID:20332423

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

dopamine receptor D2

multiple interactions
affects response to substance
increases response to substance
affects binding

Risperidone binds to and results in decreased activity of DRD2 protein
DRD2 gene polymorphism affects the susceptibility to Risperidone
DRD2 gene polymorphism results in increased susceptibility to Risperidone; DRD2 gene SNP results in increased susceptibility to Risperidone; DRD2 protein results in increased susceptibility to Risperidone
Risperidone binds to DRD2 protein
[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]; Risperidone binds to and results in decreased activity of DRD2 protein; Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]

PMID:1380082 PMID:7520908 PMID:8804920 PMID:10831489 PMID:12191584 More...

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

increases response to substance

DRD3 gene SNP results in increased susceptibility to Risperidone; DRD3 protein results in increased susceptibility to Risperidone

PMID:19506579 PMID:19997080

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dishevelled segment polarity protein 3

multiple interactions
increases expression

DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]

NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462

G

early growth response 1

decreases expression

Risperidone results in decreased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

decreases expression
multiple interactions

Risperidone results in decreased expression of EGR2 protein
Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein]]

PMID:17028028 PMID:32980479

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

erb-b2 receptor tyrosine kinase 2

increases phosphorylation

Risperidone results in increased phosphorylation of ERBB2 protein

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

Risperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

fatty acid desaturase 2

increases expression
multiple interactions

Risperidone results in increased expression of FADS2 mRNA
[Risperidone results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Risperidone promotes the reaction [Rotenone results in increased expression of FOS mRNA]
Risperidone results in increased expression of FOS mRNA
Risperidone results in increased expression of FOS protein
Dronabinol inhibits the reaction [Risperidone results in increased expression of FOS protein]; Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]]

PMID:11516571 PMID:17442543 PMID:28272498 PMID:32980479

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

affects expression

Risperidone affects the expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

gamma-glutamyltransferase 1

multiple interactions

Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein]; Risperidone results in increased expression of and results in increased secretion of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

multiple interactions

Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein]; Risperidone results in increased expression of and results in increased secretion of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions

Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; Risperidone results in increased expression of and results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 alpha

increases expression
multiple interactions

Risperidone results in increased expression of GSK3A protein
DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]

NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802

G

glycogen synthase kinase 3 beta

multiple interactions
increases expression

DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

Risperidone results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

homer scaffold protein 1

increases expression

Risperidone results in increased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

5-hydroxytryptamine receptor 1A

increases response to substance
multiple interactions

HTR1A protein results in increased susceptibility to Risperidone
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Risperidone]

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 2A

increases response to substance
affects response to substance
multiple interactions
affects binding

HTR2A gene SNP results in increased susceptibility to Risperidone; HTR2A protein results in increased susceptibility to Risperidone
HTR2A protein affects the susceptibility to Risperidone
HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; Risperidone binds to and results in decreased activity of HTR2A protein
Risperidone binds to and results in decreased activity of HTR2A protein; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein]
Risperidone binds to HTR2A protein

PMID:7520908 PMID:11927170 PMID:12191584 PMID:16314884 PMID:16948927 More...

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2C

affects response to substance
increases response to substance
multiple interactions

HTR2C gene polymorphism affects the susceptibility to Risperidone; HTR2C protein affects the susceptibility to Risperidone
HTR2C protein results in increased susceptibility to Risperidone
HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]

PMID:19142101 PMID:19997080

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

5-hydroxytryptamine receptor 6

multiple interactions

HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]

NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912

G

5-hydroxytryptamine receptor 7

multiple interactions

2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Risperidone binds to and results in decreased activity of HTR7 protein; SB 269970 inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]

PMID:18996971 PMID:19509219 PMID:20827463

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

inhibin subunit alpha

multiple interactions

Risperidone results in increased expression of [INHA protein binds to INHBB protein]

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inhibin subunit beta B

multiple interactions

Risperidone results in increased expression of [INHA protein binds to INHBB protein]

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

insulin 2

increases expression

Risperidone results in increased expression of INS protein

PMID:11927762 PMID:16601995

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

low density lipoprotein receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA]

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

monoamine oxidase A

affects response to substance
increases response to substance

MAOA gene polymorphism affects the susceptibility to Risperidone
MAOA protein results in increased susceptibility to Risperidone

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

increases expression

Risperidone results in increased expression of MAOB mRNA

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

microtubule-associated protein 2

increases expression

Risperidone results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

nerve growth factor receptor

decreases expression

Risperidone results in decreased expression of NGFR mRNA

PMID:12111809 PMID:16513140

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

neuregulin 1

increases expression

Risperidone results in increased expression of NRG1 protein

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

peroxisome proliferator-activated receptor gamma

increases expression
multiple interactions

Risperidone results in increased expression of PPARG mRNA; Risperidone results in increased expression of PPARG protein
Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 3 catalytic subunit alpha

multiple interactions
decreases expression

[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein
Risperidone results in decreased expression of PPP3CA mRNA; Risperidone results in decreased expression of PPP3CA protein

NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974

G

prolactin

multiple interactions
increases secretion
increases expression

[Risperidone co-treated with Clozapine] results in increased expression of PRL protein; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]; BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]
Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]

PMID:1380082 PMID:9696519 PMID:9989566 PMID:10084644 PMID:11048906 More...

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

regulator of G-protein signaling 2

increases expression

Risperidone results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

S100 calcium binding protein B

increases secretion

Risperidone results in increased secretion of S100B protein

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

solute carrier family 17 member 6

increases expression

Risperidone results in increased expression of SLC17A6 mRNA; Risperidone results in increased expression of SLC17A6 protein

NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542

G

synaptosome associated protein 25

affects response to substance

SNAP25 gene SNP affects the susceptibility to Risperidone

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

superoxide dismutase 1

multiple interactions
increases expression

Risperidone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]
Risperidone results in increased expression of SOD1 mRNA

PMID:12111809 PMID:12752374 PMID:16564057

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

sterol regulatory element binding transcription factor 1

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein]
Risperidone results in increased expression of SREBF1 mRNA; Risperidone results in increased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 3

multiple interactions

Risperidone inhibits the reaction [Rotenone results in decreased expression of STAT3 mRNA]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tyrosine hydroxylase

increases expression

Risperidone results in increased expression of TH protein

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

sertindole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

sertindole results in decreased activity of KCNH2 protein
sertindole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

PMID:16278312 PMID:21158687 PMID:24052561

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19841
chemical entity	19839
atom	19839
nonmetal atom	19777
nitrogen atom	18962
nitrogen molecular entity	18962
organonitrogen compound	18812
organonitrogen heterocyclic compound	18154
piperidines	7741
heteroarylpiperidine	149
(11S)-8-chloro-11-[1-(methylsulfonyl)piperidin-4-yl]-6-piperazin-1-yl-11H-benzo[5,6]cyclohepta[1,2-b]pyridine	0
(3R,4R)-1-\{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl\}-4-(2,4,5-trifluorophenyl)piperidin-3-amine	0
(5R)-6-hydroxy-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-phenyluracil	0
(8aS)-7-[(6-chloronaphthalen-2-yl)sulfonyl]-8a-(methoxymethyl)-1'-pyridin-4-yltetrahydro-5H-spiro[1,3-oxazolo[3,2-a]pyrazine-2,4'-piperidin]-5-one	0
1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1H)-one	0
2-[4-(\{2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl\}amino)-4-methylpiperidin-1-yl]isonicotinic acid	0
3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate +	15
3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one +	0
4-\{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl\}piperidine-1-carboxamide +	28
N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide	0
domperidone +	20
nadifloxacin +	1
naratriptan +	2
pimozide	6
piperidinylimidazole +	0
pyrazolylpiperidine +	55
pyridazinylpiperidine +	0
pyridylpiperidine +	0
risperidone	65
sertindole	1
Path 2
Term	Annotations
CHEBI ontology	19841
subatomic particle	19839
composite particle	19839
hadron	19839
baryon	19839
nucleon	19839
atomic nucleus	19839
atom	19839
main group element atom	19789
p-block element atom	19789
carbon group element atom	19737
carbon atom	19733
organic molecular entity	19733
organic molecule	19686
organic cyclic compound	19498
organic heterocyclic compound	18876
organic heteromonocyclic compound	17804
piperidines	7741
heteroarylpiperidine	149
(11S)-8-chloro-11-[1-(methylsulfonyl)piperidin-4-yl]-6-piperazin-1-yl-11H-benzo[5,6]cyclohepta[1,2-b]pyridine	0
(3R,4R)-1-\{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl\}-4-(2,4,5-trifluorophenyl)piperidin-3-amine	0
(5R)-6-hydroxy-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-phenyluracil	0
(8aS)-7-[(6-chloronaphthalen-2-yl)sulfonyl]-8a-(methoxymethyl)-1'-pyridin-4-yltetrahydro-5H-spiro[1,3-oxazolo[3,2-a]pyrazine-2,4'-piperidin]-5-one	0
1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1H)-one	0
2-[4-(\{2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl\}amino)-4-methylpiperidin-1-yl]isonicotinic acid	0
3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate +	15
3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one +	0
4-\{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl\}piperidine-1-carboxamide +	28
N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide	0
domperidone +	20
nadifloxacin +	1
naratriptan +	2
pimozide	6
piperidinylimidazole +	0
pyrazolylpiperidine +	55
pyridazinylpiperidine +	0
pyridylpiperidine +	0
risperidone	65
sertindole	1

paths to the root